280 related articles for article (PubMed ID: 29478735)
1. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
Pal SK; Hoffman-Censits J; Zheng H; Kaiser C; Tayama D; Bellmunt J
Eur Urol; 2018 May; 73(5):800-806. PubMed ID: 29478735
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.
Perez-Gracia JL; Loriot Y; Rosenberg JE; Powles T; Necchi A; Hussain SA; Morales-Barrera R; Retz MM; Niegisch G; Durán I; Théodore C; Grande E; Shen X; Wang J; Nelson B; Derleth CL; van der Heijden MS
Eur Urol; 2018 Mar; 73(3):462-468. PubMed ID: 29273410
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A
Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948
[TBL] [Abstract][Full Text] [Related]
6. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Sharma P; Retz M; Siefker-Radtke A; Baron A; Necchi A; Bedke J; Plimack ER; Vaena D; Grimm MO; Bracarda S; Arranz JÁ; Pal S; Ohyama C; Saci A; Qu X; Lambert A; Krishnan S; Azrilevich A; Galsky MD
Lancet Oncol; 2017 Mar; 18(3):312-322. PubMed ID: 28131785
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
Petrylak DP; Powles T; Bellmunt J; Braiteh F; Loriot Y; Morales-Barrera R; Burris HA; Kim JW; Ding B; Kaiser C; Fassò M; O'Hear C; Vogelzang NJ
JAMA Oncol; 2018 Apr; 4(4):537-544. PubMed ID: 29423515
[TBL] [Abstract][Full Text] [Related]
9. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.
Necchi A; Joseph RW; Loriot Y; Hoffman-Censits J; Perez-Gracia JL; Petrylak DP; Derleth CL; Tayama D; Zhu Q; Ding B; Kaiser C; Rosenberg JE
Ann Oncol; 2017 Dec; 28(12):3044-3050. PubMed ID: 28950298
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Balar AV; Galsky MD; Rosenberg JE; Powles T; Petrylak DP; Bellmunt J; Loriot Y; Necchi A; Hoffman-Censits J; Perez-Gracia JL; Dawson NA; van der Heijden MS; Dreicer R; Srinivas S; Retz MM; Joseph RW; Drakaki A; Vaishampayan UN; Sridhar SS; Quinn DI; Durán I; Shaffer DR; Eigl BJ; Grivas PD; Yu EY; Li S; Kadel EE; Boyd Z; Bourgon R; Hegde PS; Mariathasan S; Thåström A; Abidoye OO; Fine GD; Bajorin DF;
Lancet; 2017 Jan; 389(10064):67-76. PubMed ID: 27939400
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
Drakaki A; Powles T; Bamias A; Martin-Liberal J; Shin SJ; Friedlander T; Tosi D; Park C; Gomez-Roca C; Joly Lobbedez F; Castellano D; Morales-Barrera R; Moreno-Candilejo I; Fléchon A; Yuen K; Rishipathak D; DuPree K; Young F; Michielin F; Shemesh CS; Steinberg EE; Williams P; Lee JL
Clin Cancer Res; 2023 Nov; 29(21):4373-4384. PubMed ID: 37651261
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
Sharma P; Callahan MK; Bono P; Kim J; Spiliopoulou P; Calvo E; Pillai RN; Ott PA; de Braud F; Morse M; Le DT; Jaeger D; Chan E; Harbison C; Lin CS; Tschaika M; Azrilevich A; Rosenberg JE
Lancet Oncol; 2016 Nov; 17(11):1590-1598. PubMed ID: 27733243
[TBL] [Abstract][Full Text] [Related]
14. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
Passalacqua R; Lazzarelli S; Donini M; Montironi R; Tambaro R; De Giorgi U; Pignata S; Palumbo R; Ceresoli GL; Del Conte G; Tonini G; Morelli F; Nolè F; Panni S; Rondini E; Guida A; Zucali PA; Doni L; Iezzi E; Caminiti C
BMC Cancer; 2017 Jul; 17(1):493. PubMed ID: 28724419
[TBL] [Abstract][Full Text] [Related]
15. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
[TBL] [Abstract][Full Text] [Related]
16. Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.
Rozzi A; Salerno M; Bordin F; De Marco F; Di Nicola S; Lanzetta G
Med Oncol; 2011 Dec; 28 Suppl 1():S426-32. PubMed ID: 21116878
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies.
Barata PC; Gopalakrishnan D; Koshkin VS; Mendiratta P; Karafa M; Allman K; Martin A; Beach J; Profusek P; Tyler A; Wood L; Ornstein M; Gilligan T; Rini BI; Garcia JA; Grivas P
Target Oncol; 2018 Jun; 13(3):353-361. PubMed ID: 29623487
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.
Galsky MD; Wang H; Hahn NM; Twardowski P; Pal SK; Albany C; Fleming MT; Starodub A; Hauke RJ; Yu M; Zhao Q; Sonpavde G; Donovan MJ; Patel VG; Sfakianos JP; Domingo-Domenech J; Oh WK; Akers N; Losic B; Gnjatic S; Schadt EE; Chen R; Kim-Schulze S; Bhardwaj N; Uzilov AV
Eur Urol; 2018 May; 73(5):751-759. PubMed ID: 29248319
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
Apolo AB; Nadal R; Tomita Y; Davarpanah NN; Cordes LM; Steinberg SM; Cao L; Parnes HL; Costello R; Merino MJ; Folio LR; Lindenberg L; Raffeld M; Lin J; Lee MJ; Lee S; Alarcon SV; Yuno A; Dawson NA; Allette K; Roy A; De Silva D; Lee MM; Sissung TM; Figg WD; Agarwal PK; Wright JJ; Ning YM; Gulley JL; Dahut WL; Bottaro DP; Trepel JB
Lancet Oncol; 2020 Aug; 21(8):1099-1109. PubMed ID: 32645282
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
Powles T; O'Donnell PH; Massard C; Arkenau HT; Friedlander TW; Hoimes CJ; Lee JL; Ong M; Sridhar SS; Vogelzang NJ; Fishman MN; Zhang J; Srinivas S; Parikh J; Antal J; Jin X; Gupta AK; Ben Y; Hahn NM
JAMA Oncol; 2017 Sep; 3(9):e172411. PubMed ID: 28817753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
